CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three core priorities: “First ...
Hosted on MSN
Scholar Rock outlines 2026 apitegromab BLA resubmission and commercial launch following FDA progress
Earnings Call Insights: Scholar Rock Holding Corporation (SRRK) Q4 2025 CEO David Hallal stated that "Scholar Rock is poised for a transformative year in 2026," emphasizing the company's focus on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results